| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/ANNONC/MDY308 |
| P698 | PubMed publication ID | 30285213 |
| P2093 | author name string | A Vogel | |
| B Daniele | |||
| I Chau | |||
| D Arnold | |||
| T Meyer | |||
| A Cervantes | |||
| P Schirmacher | |||
| C Verslype | |||
| J Ricke | |||
| E Martinelli | |||
| C J Zech | |||
| B Sangro | |||
| U Neumann | |||
| ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org | |||
| J Llovet | |||
| J M Llovet | |||
| J-C Nault | |||
| P433 | issue | Supplement_4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | iv238-iv255 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| P478 | volume | 29 | |
| 29 Suppl 4 |
| Q96135403 | A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma |
| Q92593918 | ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization |
| Q96165774 | Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study |
| Q92298671 | Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis |
| Q89849404 | Case Report of Synchronous Prostate, Hepatocellular, and Rectal Carcinomas and Review of the Literature |
| Q64969945 | Combination of radiofrequency ablation and transcatheter arterial chemoembolization to treat hepatocellular carcinoma: measurement of distance from needle tip to nodule for assessment of local tumor progression. |
| Q89623916 | Controversies in the management of hepatocellular carcinoma |
| Q97520657 | Cured giant hepatocellular carcinoma after transarterial embolization complicated with liver abscess formation |
| Q96342307 | Deep learning-based classification and mutation prediction from histopathological images of hepatocellular carcinoma |
| Q90862879 | Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome |
| Q96304229 | Development and Validation of Pre- and Post-Operative Models to Predict Recurrence After Resection of Solitary Hepatocellular Carcinoma: A Multi-Institutional Study |
| Q64100196 | Downregulation of nucleolar and spindle-associated protein 1 expression suppresses liver cancer cell function |
| Q91993433 | Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization |
| Q98289959 | Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review |
| Q64238257 | Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models |
| Q59807385 | Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid |
| Q90190641 | Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition |
| Q89967093 | Hepatic Resection Is Associated With Improved Long-Term Survival Compared to Radio-Frequency Ablation in Patients With Multifocal Hepatocellular Carcinoma |
| Q91981419 | Human Liver Regeneration: An Etiology Dependent Process |
| Q99617222 | Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus-associated early stage hepatocellular carcinoma based on RNA-sequencing data |
| Q90296820 | Letter to the Editor: Hepatic Resection Compared to Chemoembolization in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Comment For Moving Forward |
| Q92458709 | Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west |
| Q64263728 | Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization |
| Q99636467 | Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study |
| Q90091447 | Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis |
| Q93068290 | Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort |
| Q93385532 | Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma |
| Q93334976 | Recommendations on the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19 |
| Q92571307 | SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma |
| Q92454698 | Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study |
| Q90152032 | Surveillance and diagnosis of hepatocellular carcinoma: A systematic review |
| Q99713392 | The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis |
| Q90423541 | The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers |
| Q64259929 | Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures |
| Q101377881 | Therapeutic Ultrasound Parameter Optimization for Drug Delivery Applied to a Murine Model of Hepatocellular Carcinoma |
| Q98946921 | Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future |
| Q90644228 | Treatment Lines in Hepatocellular Carcinoma |
| Q92250918 | Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis |
| Q60909319 | Weighing the benefits of hepatocellular carcinoma surveillance against potential harms |
| Q64273870 | YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role |
Search more.